Washington - Get the facts first, then regulate. So urged Rajesh Balkirshnan, Ph.D., associate professor of management and policy sciences at the University of Texas School of Public Health in Houston.
Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
FDA Issues Alert on Counterfeit Botox: What Dermatology Clinicians Need to Know
ReV Up Your Vitiligo Treatment Strategies
Reviewing the Rosacea Pipeline: A Look at the Last 10 Years
Is Your Texting as Caring as Your Bedside Manner?